Valuation: CombiGene AB

Market Cap 44.35M 4.46M 3.92M 3.7M 3.37M 6.31M 428M 6.36M 17.19M 218M 16.74M 16.37M 709M P/E 2024
-1.05x
P/E 2025 -3.62x
Enterprise Value 38.51M 3.87M 3.4M 3.21M 2.93M 5.48M 372M 5.52M 14.92M 189M 14.53M 14.22M 615M EV / Sales 2024
-13.3x
EV / Sales 2025 128x
Free-Float
53.9%
Yield 2024
8.4%
Yield 2025 88.5%
1 day-4.68%
1 week-5.88%
Current month-3.86%
1 month+1.82%
3 months-5.08%
6 months+4.19%
Current year-0.88%
1 week 2.24
Extreme 2.24
2.38
1 month 2.16
Extreme 2.16
2.42
Current year 1.75
Extreme 1.75
2.6
1 year 1.75
Extreme 1.75
2.87
3 years 1.27
Extreme 1.27
5.95
5 years 1.27
Extreme 1.27
20.05
10 years 1.27
Extreme 1.27
147
Manager TitleAgeSince
Chief Executive Officer 48 30/07/2025
Director TitleAgeSince
Director/Board Member 54 09/12/2024
Chairman 55 10/06/2026
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-4.68%-5.88%0.00%-62.29% 4.46M
-3.30%+1.19%+54.62%+104.15% 71.94B
-0.12%-3.82%+34.21%+74.86% 59.35B
+2.50%+5.66%+33.00%+21.74% 27.16B
+2.71%-1.96%-13.79%+364.46% 26.54B
+0.81%+0.61%-0.49%-5.14% 24.93B
-1.05%+1.07%+21.45%-10.32% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.17%-8.07%+499.10% 14.2B
+2.15%-0.92%+48.93%+169.79% 14.36B
Average -0.25%-0.69%+31.67%+148.20% 27.41B
Weighted average by Cap. -0.36%-0.24%+35.44%+132.35%

Financials

2024 2025
Net sales 2M 201K 177K 167K 152K 284K 19.29M 286K 775K 9.82M 754K 738K 31.94M 304K 30.55K 26.87K 25.33K 23.11K 43.22K 2.93M 43.56K 118K 1.49M 115K 112K 4.86M
Net income -44.88M -4.51M -3.97M -3.74M -3.41M -6.38M -433M -6.43M -17.39M -220M -16.93M -16.57M -717M -12.36M -1.24M -1.09M -1.03M -940K -1.76M -119M -1.77M -4.79M -60.68M -4.66M -4.56M -197M
Net Debt -73.75M -7.41M -6.52M -6.15M -5.61M -10.49M -711M -10.57M -28.58M -362M -27.83M -27.22M -1.18B -5.84M -587K -516K -487K -444K -831K -56.36M -837K -2.26M -28.68M -2.2M -2.16M -93.34M
Logo CombiGene AB
Larkberget AB, formerly Combigene AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Employees
1
Date Price Change Volume
24/09/26 SEK 2.240 -4.68% 1,442
23/09/26 SEK 2.350 -0.42% 1,741
22/09/26 SEK 2.360 +0.43% 3,725
21/09/26 SEK 2.350 +4.91% 13,473
18/09/26 SEK 2.240 -5.88% 7,781
  1. Stock Market
  2. Stocks
  3. LARK Stock